Last updated on March 2019

Study of Sulfatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma


Brief description of study

A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of sulfatinib as a second-line treatment in patients with surgically unresectable or metastatic biliary tract carcinoma

Detailed Study Description

This study adopt Simon's two-stage designs method based on the primary endpoint of 16-week PFS rates. In the first stage, 16 patients will be recruited. If there are 3 or fewer patients without progression or death out of these 16 patients at week 16, the study will be stopped. Otherwise, 16 additional patients will be accrued for a total of 32 evaluable patients.

Sulfatinib will be orally administered within 1 hour after breakfast once a day (QD) for every 28-day treatment cycle until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met (which comes first).

Clinical Study Identifier: NCT02966821

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.